PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;:JCO2400003 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer Biomark. 2024;41(1):83-91 - PMID: 39269823 - DOI: 10.3233/CBM-230431
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - DOI: 10.1038/s42255-024-01105-9
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models.
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Cancers (Basel). 2023;15(19):ePub - PMID: 37835569 - PMCID: PMC10571776 - DOI: 10.3390/cancers15194875
Scirrhous HCC: Another 'omic thread in the HCC tapestry.
Hepatology. 2023;79(4):747-748 - PMID: 37725712 - DOI: 10.1097/HEP.0000000000000609
Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment.
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Gastric Cancer. 2023;26(6):934-946 - PMID: 37668884 - DOI: 10.1007/s10120-023-01429-7
Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4D Blood Flow Simulations.
Int J Radiat Oncol Biol Phys. 2023;116(5):1226-1233 - PMID: 36739919 - PMCID: PMC10363211 - DOI: 10.1016/j.ijrobp.2023.01.054
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
NPJ Precis Oncol. 2023;7(1):24 - PMID: 36864234 - PMCID: PMC9981559 - DOI: 10.1038/s41698-023-00358-z
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.
Cancers (Basel). 2023;15(4):ePub - PMID: 36831366 - PMCID: PMC9954510 - DOI: 10.3390/cancers15041021
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.
Clin Cancer Res. 2023;29(8):1605-1619 - PMID: 36749873 - PMCID: PMC10106451 - DOI: 10.1158/1078-0432.CCR-22-1630
Predictive Model of Liver Toxicity to Aid the Personalized Selection of Proton vs Photon Therapy in Hepatocellular Carcinoma.
Int J Radiat Oncol Biol Phys. 2023;116(5):1234-1243 - PMID: 36739920 - DOI: 10.1016/j.ijrobp.2023.01.055
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
Gut. 2023;72(6):1196-1210 - PMID: 36596711 - DOI: 10.1136/gutjnl-2022-328428
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Anticancer Res. 2022;42(11):5205-5215 - PMID: 36288859 - DOI: 10.21873/anticanres.16027
Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers.
Hepatology. 2022;77(6):1943-1957 - PMID: 36052732 - DOI: 10.1002/hep.32769
Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
Chirurgia (Bucur). 2022;117(4):407-414 - PMID: 36049097 - DOI: 10.21614/chirurgia.2772
Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis.
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Clin Cancer Res. 2022;28(18):3950-3957 - PMID: 35833850 - PMCID: PMC9481695 - DOI: 10.1158/1078-0432.CCR-22-1169
Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition.
Clin Cancer Res. 2022;28(14):3076-3090 - PMID: 35584239 - PMCID: PMC9355624 - DOI: 10.1158/1078-0432.CCR-22-0486
VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051
Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
JAMA Oncol. 2021;7(7):1051-1059 - PMID: 33885725 - PMCID: PMC8668197 - DOI: 10.1001/jamaoncol.2021.0168
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies.
Cancers (Basel). 2021;13(22):ePub - PMID: 34830880 - PMCID: PMC8616228 - DOI: 10.3390/cancers13225725
Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas.
Cancers (Basel). 2021;13(19):ePub - PMID: 34638408 - PMCID: PMC8507866 - DOI: 10.3390/cancers13194919
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
NPJ Precis Oncol. 2021;5(1):62 - PMID: 34188163 - PMCID: PMC8242049 - DOI: 10.1038/s41698-021-00197-w
Fatty acid synthesis is required for breast cancer brain metastasis
Nature Cancer. 2021;:ePub
Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers.
JCO Clin Cancer Inform. 2021;5:315-325 - PMID: 33764817 - PMCID: PMC8462658 - DOI: 10.1200/CCI.20.00118
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature. 2021;592(7854):450-456 - PMID: 33762733 - PMCID: PMC8046670 - DOI: 10.1038/s41586-021-03362-0
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients.
Clin Cancer Res. 2021;27(4):1048-1057 - PMID: 33199490 - PMCID: PMC8284901 - DOI: 10.1158/1078-0432.CCR-20-2500
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.
Neurooncol Adv. 2020;2(1):vdaa157 - PMID: 33392506 - PMCID: PMC7764510 - DOI: 10.1093/noajnl/vdaa157
Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Clin Cancer Res. 2020;26(23):6158-6167 - PMID: 32878766 - DOI: 10.1158/1078-0432.CCR-20-1310
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33234602 - PMCID: PMC7689089 - DOI: 10.1136/jitc-2020-001435
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.
Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers.
Mol Ther Oncolytics. 2020;18:546-555 - PMID: 32839735 - PMCID: PMC7437509 - DOI: 10.1016/j.omto.2020.08.007
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?
Circ Res. 2020;127(6):724-726 - PMID: 32853096 - PMCID: PMC7462096 - DOI: 10.1161/CIRCRESAHA.120.317720
Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients.
Cancers (Basel). 2020;12(5):ePub - PMID: 32443546 - PMCID: PMC7281651 - DOI: 10.3390/cancers12051275
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - PMCID: PMC6997488 - DOI: 10.1016/j.ebiom.2020.102644
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res. 2020;26(1):206-212 - PMID: 31558474 - PMCID: PMC7139851 - DOI: 10.1158/1078-0432.CCR-19-1739
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
J Clin Oncol. 2019;37(35):3446-3454 - PMID: 31626572 - PMCID: PMC7098833 - DOI: 10.1200/JCO.19.01367
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy.
Clin Transl Radiat Oncol. 2019;18:113-119 - PMID: 31341986 - PMCID: PMC6630151 - DOI: 10.1016/j.ctro.2019.04.013
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol.
Endosc Ultrasound. 2019;8(4):235-240 - PMID: 31249159 - PMCID: PMC6714481 - DOI: 10.4103/eus.eus_16_19
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019;5(7):1020-1027 - PMID: 31145418 - PMCID: PMC6547247 - DOI: 10.1001/jamaoncol.2019.0892
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
Clin Cancer Res. 2018;24(19):4643-4649 - PMID: 29941486 - DOI: 10.1158/1078-0432.CCR-18-1025
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
Int J Radiat Oncol Biol Phys. 2018;101(5):1222-1225 - PMID: 29859792 - PMCID: PMC6050125 - DOI: 10.1016/j.ijrobp.2018.04.026
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Sci Transl Med. 2018;10(432):ePub - PMID: 29540614 - PMCID: PMC5936748 - DOI: 10.1126/scitranslmed.aag0945
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol. 2018;15(5):325-340 - PMID: 29508855 - PMCID: PMC5921900 - DOI: 10.1038/nrclinonc.2018.29
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J. 2017;5(7):987-996 - PMID: 29163965 - PMCID: PMC5676550 - DOI: 10.1177/2050640617695698
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017;7(10):1116-1135 - PMID: 28667006 - PMCID: PMC5628134 - DOI: 10.1158/2159-8290.CD-17-0368
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Sci Transl Med. 2017;9(391):ePub - PMID: 28539475 - PMCID: PMC5917603 - DOI: 10.1126/scitranslmed.aal4682
The brain microenvironment mediates resistance in luminal breast cancer to
PI3K inhibition through HER3 activation
Science Translational Medicine. 2017;9(391):eaal4682
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
Onco Targets Ther. 2017;10:1403-1412 - PMID: 28424556 - PMCID: PMC5344425 - DOI: 10.2147/OTT.S111681
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.
Am J Cancer Res. 2017;7(3):484-502 - PMID: 28401006 - PMCID: PMC5385638
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis. 2017;20(2):185-204 - PMID: 28361267 - PMCID: PMC5439974 - DOI: 10.1007/s10456-017-9552-y
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.
Ecancermedicalscience. 2016;10:689 - PMID: 27994645 - PMCID: PMC5130328 - DOI: 10.3332/ecancer.2016.689
Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27908927 - PMCID: PMC5131752 - DOI: 10.1101/cshperspect.a031195
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Sci Transl Med. 2016;8(360):360ra135 - PMID: 27733559 - PMCID: PMC5457741 - DOI: 10.1126/scitranslmed.aaf5219
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27663981 - PMCID: PMC5131751 - DOI: 10.1101/cshperspect.a027094
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
Radiother Oncol. 2016;120(2):185-94 - PMID: 27495145 - DOI: 10.1016/j.radonc.2016.07.013
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.
EBioMedicine. 2016;8:195-202 - PMID: 27428430 - PMCID: PMC4919562 - DOI: 10.1016/j.ebiom.2016.04.034
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113
A protein and mRNA expression-based classification of gastric cancer.
Mod Pathol. 2016;29(7):772-84 - PMID: 27032689 - DOI: 10.1038/modpathol.2016.55
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
J Clin Oncol. 2016;34(14):1669-75 - PMID: 26976425 - PMCID: PMC4872317 - DOI: 10.1200/JCO.2015.64.3817
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy.
AJR Am J Roentgenol. 2016;206(5):987-93 - PMID: 26934729 - DOI: 10.2214/AJR.15.15528
PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity.
Clin Cancer Res. 2016;22(12):2993-3004 - PMID: 26861455 - PMCID: PMC4911258 - DOI: 10.1158/1078-0432.CCR-15-1839
Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
Cancer Genomics Proteomics. 2015;12(1):21-30 - PMID: 25560641
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Clin Cancer Res. 2015;21(16):3610-8 - PMID: 25910950 - PMCID: PMC4790106 - DOI: 10.1158/1078-0432.CCR-14-3220
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Proc Natl Acad Sci U S A. 2015;112(46):14325-14330 - PMID: 26578779 - PMCID: PMC4655544 - DOI: 10.1073/pnas.1518808112
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
Oncoimmunology. 2015;4(10):e1029703 - PMID: 26451297 - PMCID: PMC4589048 - DOI: 10.1080/2162402X.2015.1029703
Vascular diseases await translation of blood vessels engineered from stem cells.
Sci Transl Med. 2015;7(309):309rv6 - PMID: 26468328 - PMCID: PMC4799660 - DOI: 10.1126/scitranslmed.aaa1805
Familial Gastric Cancers.
Oncologist. 2015;20(12):1365-1377 - PMID: 26424758 - PMCID: PMC4679084 - DOI: 10.1634/theoncologist.2015-0205
From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey.
Cancer J. 2015;21(4):235-236 - PMID: 26222072 - PMCID: PMC4791947 - DOI: 10.1097/PPO.0000000000000136
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Chemotherapy and antiangiogenics in biliary tract cancer.
Lancet Oncol. 2015;16(8):882-3 - PMID: 26179202 - DOI: 10.1016/S1470-2045(15)00093-5
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors.
J Am Chem Soc. 2015;137(31):9832-42 - PMID: 26149349 - PMCID: PMC4750386 - DOI: 10.1021/jacs.5b04765
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.
Proc Natl Acad Sci U S A. 2015;112(27):E3454 - PMID: 26080434 - PMCID: PMC4500270 - DOI: 10.1073/pnas.1507225112
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
J Natl Cancer Inst. 2015;107(9):ePub - PMID: 26063793 - PMCID: PMC4651102 - DOI: 10.1093/jnci/djv155
Lessons From 30 Years of Teaching About the Microenvironment of Tumors.
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma.
J Comput Assist Tomogr. 2015;39(4):607-612 - PMID: 25793653 - PMCID: PMC4504795 - DOI: 10.1097/RCT.0000000000000239
Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma.
J Clin Oncol. 2015;33(10):1197-213 - PMID: 25713439 - PMCID: PMC4517055 - DOI: 10.1200/JCO.2014.55.9575
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304 - DOI: 10.1073/pnas.1421632111
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Proc Natl Acad Sci U S A. 2015;112(5):1547-52 - PMID: 25605928 - PMCID: PMC4321320 - DOI: 10.1073/pnas.1424024112
CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression.
AJR Am J Roentgenol. 2015;204(1):W11-8 - PMID: 25539263 - PMCID: PMC4479405 - DOI: 10.2214/AJR.13.12412
Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Translation of anticancer efficacy from nonclinical models to the clinic.
CPT Pharmacometrics Syst Pharmacol. 2014;3:e128 - PMID: 25098530 - PMCID: PMC4150926 - DOI: 10.1038/psp.2014.28
Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism.
Med Hypotheses. 2014;83(4):477-81 - PMID: 25175713 - DOI: 10.1016/j.mehy.2014.08.004
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation.
Neuro Oncol. 2014;16 Suppl 3:iii12 - PMID: 25165209 - PMCID: PMC4144509
Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.
J Natl Cancer Inst. 2014;106(8):ePub - PMID: 25082335 - DOI: 10.1093/jnci/dju187
Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy.
In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (Editor: LM McManus & RN Mitchell). Elsevier Press, Oxford. 2014;:(in press)
Molecular Pathophysiology of Tumors.
In: Principles and Practice of Radiation Oncology, 6th Edition (Editors: E. C. Halperin, C. A. Parez, L. W. Brady), Lippincott, Williams & Wilkins, New York. 2014;Chapter 4:(in press)
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180 - DOI: 10.1016/j.ijrobp.2014.03.034
Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells.
Pancreas. 2014;43(5):795-800 - PMID: 24658318 - DOI: 10.1097/MPA.0000000000000106
Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry.
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 2013;45(12):1474-8 - PMID: 24185513 - DOI: 10.1038/ng.2806
Benefits of Vascular Normalization Are Dose and Time Dependent--Letter.
Cancer Res. 2013;73(23):7144-6 - PMID: 24265277 - PMCID: PMC3876035 - DOI: 10.1158/0008-5472.CAN-13-1989
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Proc Natl Acad Sci U S A. 2013;110(47):19059-64 - PMID: 24190997 - PMCID: PMC3839699 - DOI: 10.1073/pnas.1318022110
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2 in Patients with Advanced Hepatocellular Cancer.
Clin Cancer Res. 2013;19(23):6614-23 - PMID: 24088738 - PMCID: PMC4795808 - DOI: 10.1158/1078-0432.CCR-13-1442
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
J Natl Cancer Inst. 2013;105(16):1188-1201 - PMID: 23899555 - PMCID: PMC3748004 - DOI: 10.1093/jnci/djt164
Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
Proc Natl Acad Sci U S A. 2013;110(31):12774-9 - PMID: 23861493 - PMCID: PMC3732948 - DOI: 10.1073/pnas.1310675110
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?
J Natl Cancer Inst. 2013;105(11):762-5 - PMID: 23670727 - PMCID: PMC3672078 - DOI: 10.1093/jnci/djt114
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Cancer Res. 2013;73(10):2943-8 - PMID: 23440426 - PMCID: PMC3655127 - DOI: 10.1158/0008-5472.CAN-12-4354
Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423 - DOI: 10.1158/1078-0432.CCR-12-3041
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Proc Natl Acad Sci U S A. 2012;109(43):17561-6 - PMID: 23045683 - PMCID: PMC3491458 - DOI: 10.1073/pnas.1215397109
Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Oncology (Williston Park). 2012;26(8):741-3 - PMID: 22957407 - PMCID: PMC3682651
Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?
J Natl Cancer Inst. 2012;104(12):899-905 - PMID: 22572994 - PMCID: PMC3379722 - DOI: 10.1093/jnci/djs239
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma.
Pancreas. 2012;41(7):1001-7 - PMID: 22722257 - DOI: 10.1097/MPA.0b013e3182546e13
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170 - DOI: 10.1634/theoncologist.2011-0321
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
An isolated tumor perfusion model in mice.
Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.
A transient parabiosis skin transplantation model in mice.
Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression.
Am J Cancer Res. 2011;1(2):144-54 - PMID: 21822499 - PMCID: PMC3150110
Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010
Is vasculogenesis crucial for the regrowth of irradiated tumours?
HCC and angiogenesis: possible targets and future directions.
Nat Rev Clin Oncol. 2011;8(5):292-301 - PMID: 21386818 - PMCID: PMC3266719 - DOI: 10.1038/nrclinonc.2011.30
Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer
Angiogenesis Foundation CME e-publication. 2011;:ePub
Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape.
Cancer Res. 2011;71(1):19-28 - PMID: 21199795 - PMCID: PMC3074948 - DOI: 10.1158/0008-5472.CAN-10-2602
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Proc Natl Acad Sci U S A. 2011;108(9):3725-30 - PMID: 21321210 - PMCID: PMC3048115 - DOI: 10.1073/pnas.1100446108
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33 - PMID: 21833345 - PMCID: PMC3151740 - DOI: 10.1016/j.cloc.2011.04.003
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
Microcirculation. 2010;17(3):206-25 - PMID: 20374484 - PMCID: PMC2859831 - DOI: 10.1111/j.1549-8719.2010.00029.x
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010;28(17):2817-23 - PMID: 20458050 - PMCID: PMC2903316 - DOI: 10.1200/JCO.2009.26.3988
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.
Cancer Res. 2010;70(14):5679-85 - PMID: 20631066 - PMCID: PMC2918387 - DOI: 10.1158/0008-5472.CAN-09-4446
The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients.
Nat Clin Pract Oncol. 2009;6:229-36
Visualizing anti-tumor immune responses in vivo.
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo.
Am J Pathol. 2009;175(1):294-302 - PMID: 19477947 - PMCID: PMC2708815 - DOI: 10.2353/ajpath.2009.080887
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
J Clin Oncol. 2009;27(18):3027-35 - PMID: 19470923 - PMCID: PMC2702235 - DOI: 10.1200/JCO.2008.20.9908
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Nat Rev Clin Oncol. 2009;6(4):229-36 - PMID: 19333229 - PMCID: PMC4793889 - DOI: 10.1038/nrclinonc.2009.14
VEGFR1-activity-independent metastasis formation.
Nature. 2009;461(7262):E4; discussion E5 - PMID: 19759568 - PMCID: PMC3065241 - DOI: 10.1038/nature08254
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099
Emerging paradigms and potential biomarkers of response and resistance in anatiangiogenic therapy of cancer
ASCO 2009 Educational Book. 2009;:716-21
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).
J Cell Mol Med. 2009;13(9B):3720-9 - PMID: 19426150 - PMCID: PMC2832073 - DOI: 10.1111/j.1582-4934.2009.00785.x
Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464
Normalization of tumor vasculature and microenvironment.
In: Angiogenesis: An Integrative Approach from Science to Medicine (Editors: W. D. Figg and J. Folkman), Springer. 2008;:173-282
Vascular and interstitial biology of tumors
In: Clinical Oncology. 4th Edition, (Editors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG), Elsevier, Philadelphia. 2008;:105-24
A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.
A protocol for a lung neovascularization model in rodents.
Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.
Comp Med. 2008;58(3):253-63 - PMID: 18589867 - PMCID: PMC2693079
Normalization of tumor vasculature and microenvironment.
In: Antiangiogenic Agents in Cancer Therapy. (Editors: Beverly Teicher and Lee Ellis), Humana Press. 2007;:261-76
Normalization of tumor vasculature and microenvironment by antiangiogenic therapy.
In: Angiogenesis: Mechanisms and Cancer Therapy (Editors: Dieter Marm and Norbert E. Fusenig), Springer-Verlag, Berlin. 2007;:577-92
Angiogenesis in Solid Tumors
In: Antiangiogenic Cancer Therapy (Editors: James L. Abbruzzese, Darren W. Davis and Roy S. Herbst), CRC Press, Boca Raton. 2007;:43-90
Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer.
Current Colorectal Cancer Reports. 2007;3:94-98
Detection of circulating endothelial cells: CD146- based magnetic separation enrichment or flow cytometric assay?
J Clin Oncol. 2007;25:e3-e5
Endothelial cell-based therapy for hematopoiesis
Blood. 2007;109(6):2272-3
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175
Antiangiogenic agents for the treatment of glioblastoma.
Expert Opin Investig Drugs. 2007;16(12):1895-908 - PMID: 18041999 - DOI: 10.1517/13543784.16.12.1895
Targeted therapy in rectal cancer.
Oncology (Williston Park). 2007;21(9):1055-65; discussion 1065, 1070, 1075 passim - PMID: 17910311 - PMCID: PMC2686129
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol. 2007;4(5):316-21 - PMID: 17464339 - PMCID: PMC2686127 - DOI: 10.1038/ncponc0813
American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
Trends Mol Med. 2007;13(6):223-30 - PMID: 17462954 - PMCID: PMC2686126 - DOI: 10.1016/j.molmed.2007.04.001
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120 - DOI: 10.1200/JCO.2007.11.3985
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Nat Clin Pract Oncol. 2006;3(1):24-40 - PMID: 16407877 - DOI: 10.1038/ncponc0403
Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
Cancer Res. 2006;66(8):3967-70 - PMID: 16618712 - DOI: 10.1158/0008-5472.CAN-05-4536
Platelet-derived growth factor receptor-beta in Gorham's disease.
Nat Clin Pract Oncol. 2006;3(12):693-7 - PMID: 17139320 - PMCID: PMC2693369 - DOI: 10.1038/ncponc0660
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.
Proc Natl Acad Sci U S A. 2006;103(4):855-60 - PMID: 16418262 - PMCID: PMC1348013 - DOI: 10.1073/pnas.0510412103
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
J Clin Oncol. 2006;24(9):1449-53 - PMID: 16549839 - PMCID: PMC2718681 - DOI: 10.1200/JCO.2005.04.2861
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Semin Oncol. 2006;33(5 Suppl 10):S35-40 - PMID: 17145523 - PMCID: PMC2686124 - DOI: 10.1053/j.seminoncol.2006.08.007
Engineering vascularized tissue.
Nat Biotechnol. 2005;23(7):821-3 - PMID: 16003365 - DOI: 10.1038/nbt0705-821
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
J Clin Oncol. 2005;23(31):8136-9 - PMID: 16258121 - DOI: 10.1200/JCO.2005.02.5635
Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow.
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.
Correspondence: PET concerns in bevacizumab treatment
Nature Medicine. 2004;10:561
Role of eNOS in neovascularization: NO for endothelial progenitor cells.
Trends Mol Med. 2004;10(4):143-5 - PMID: 15162796 - DOI: 10.1016/j.molmed.2004.02.001
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Differential transplantability of tumor-associated stromal cells.
Cancer Res. 2004;64(17):5920-4 - PMID: 15342367 - DOI: 10.1158/0008-5472.CAN-04-1268
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Pancreas. 2004;28(3):311-6 - PMID: 15084978 - DOI: 10.1097/00006676-200404000-00019
Role of bone marrow-derived cells in tumor angiogenesis and treatment.
Cancer Cell. 2003;3(6):515-6 - PMID: 12842078 - DOI: 10.1016/s1535-6108(03)00138-7
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer.
Angiogenesis. 2003;6(1):15-24 - PMID: 14517400 - DOI: 10.1023/a:1025803600840
Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Oncogene. 2003;22(44):6857-64 - PMID: 14534532 - DOI: 10.1038/sj.onc.1206751
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA
Gene therapy for pancreatic cancer based on genetic characterization of the disease.
J Hepatobiliary Pancreat Surg. 2002;9(1):32-8 - PMID: 12021895 - DOI: 10.1007/s005340200002
Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines.
Genes Chromosomes Cancer. 2002;34(2):234-42 - PMID: 11979557 - DOI: 10.1002/gcc.10060
Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Pancreas. 2002;25(2):111-21 - PMID: 12142732 - DOI: 10.1097/00006676-200208000-00001
In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells
The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice.
Pancreas. 2000;20(3):227-33 - PMID: 10766447 - DOI: 10.1097/00006676-200004000-00002
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Cancer Res. 2000;60(4):1111-6 - PMID: 10706132
Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus.
Hum Gene Ther. 2000;11(2):223-35 - PMID: 10680837 - DOI: 10.1089/10430340050015978
234